Suchergebnisse

This one-day workshop seeks to reflect on the notion of fab- rication in both personal and industrial contexts. Although these contexts are very distinct in their economical and polit- ical vision, they share important characteristics (e.g., users interacting with specific fabrication equipment and tools). The workshop topic spans from personal fabrication to (au- tomated) production, from applied to theoretical considera- tions, from user requirements to design as a crafting practice. We will address changes in production that affect humans, e.g., from mass production to Do-It-Yourself (DIY) produc- tion, in order to discuss findings and lessons learned for in- dividual and collective production workplaces of the future. We aim to explore the intersections between different dimen- sions and processes of production ranging all the way from hobbyist to professional making. Furthermore, the workshop will critically reflect on current developments and their conse- quences on personal, societal, and economical levels includ- ing questions of the reorganization of work and labor, inno- vation cultures, and politics of participation.

Background: Advanced systemic mastocytosis (advSM) is characterized by presence of the KIT D816V mutation and pathologic accumulation of neoplastic mast cells (MCs) in various tissues, leading to severe symptoms and organ damage (eg, cytopenias, liver dysfunction, portal hypertension, malabsorption, and weight loss). Treatment with midostaurin, an orally active multikinase/KIT inhibitor now approved for advSM in the United States and the European Union, resulted in a high rate of response accompanied by reduced MC infiltration of the bone marrow and lowered serum tryptase level. Objective: We aimed to determine whether midostaurin improves health-related quality of life (QOL) and MC mediator related symptoms in patients with advSM. Methods: In 116 patients with systemic mastocytosis (89 patients with advSM fulfilling the strict inclusion criteria of the D2201 study [ClinicalTrials.gov identifier NCT00782067]), QOL and symptom burden were assessed during treatment with midostaurin by using the 12-Item Short-Form Health Survey (SF-12) and the Memorial Symptom Assessment Scale patient reported questionnaires, respectively. MC mediator related symptoms were evaluated by using a specific physician-reported questionnaire Results: Over the first 6 cycles of treatment with midostaurin (ie, 6 months), patients experienced significant improvements in total SF-12 and Memorial Symptom Assessment Scale scores, as well as in subscores of each instrument. These improvements were durable during 36 months of follow-up. Similarly, we found substantial improvements (67%-100%) in all MC mediator related symptoms. Conclusion: QOL and MC mediator related symptoms significantly improve with midostaurin treatment in patients with advSM (ClinicalTrials.gov identifier, NCT00782067).